相关实验视频
Updated: Jan 6, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.5K
菲尔戈提尼布在类风湿性关节炎中的有效性:对大型多中心队列的观察分析
Eleonora Celletti1, Myriam Di Penta2, Alarico Ariani3
1Rheumatology Unit, Clinica Medica Institute, Ospedale "SS. Annunziata" di Chieti/Università "G. d'Annunzio", Chieti, Italy.
Rheumatology and therapy
|December 4, 2025
概括
菲尔戈提尼布 (FIL) 在现实世界类风湿性关节炎 (RA) 患者中显示出有效性和高的药物保留率. 这项研究证实了FIL的证实.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 随机对照试验 (RCT) 确立了filgotinib (FIL) 在类风湿性关节炎 (RA) 中的疗效和安全性.
- 在临床实践中,关于FIL在临床实践中的有效性,持久性,耐受性和安全性的现实数据有限.
- 这项研究解决了在RA管理中对FIL的实际证据的需求.
研究的目的:
- 评估filgotinib (FIL) 在风湿性关节炎 (RA) 患者的实际有效性.
- 在多样化的RA患者队列中评估FIL的药物保留率 (DRR).
- 在常规临床环境中确定影响FIL持久性的因素.
主要方法:
- 多中心回顾性队列研究,涉及27个意大利风湿病中心的204名RA患者.
- 卡普兰-梅尔法用于估计药物保留率 (DRR).
- 多变量考克斯回归分析了影响药物存活的因素;DAS28-CRP在基线,6个月和12个月评估.
主要成果:
- 观察到高的药物保留率:6个月后90.2%,12个月后75.1%,18个月后64.7%.
- 较低的DRR与以后的治疗线和类风湿因子阳性相关.
- 通过DAS28-CRP反应显示的显著有效性:36.1%在6个月内实现了缓解,在12个月后增加到50.0%.
结论:
- 现实世界的数据证实了filgotinib (FIL) 在风湿性关节炎 (RA) 管理中是有效的.
- 在临床实践中,FIL显示了良好的药物保留率和良好的DAS28-CRP反应.
- 这项研究支持FIL作为RA患者在受控试验环境之外的治疗选择的实用性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
The JAK-STAT Signaling Pathway
11.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447
Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427

